Медико-биологический
информационный портал
для специалистов
 
Medline.ru

СОДЕРЖАНИЕ ЖУРНАЛА:
Физико-химическая биология

Клиническая медицина

Профилактическая медицина

Медико-биологические науки


АРХИВ:

Фундаментальные исследования

Организация здравохраниения

История медицины и биологии



Последние публикации

Поиск публикаций

Articles

Архив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г.  2021 г.  2022 г.  2023 г. 

Редакционная информация:
        Опубликовать статью
        Наша статистика


 РЕДАКЦИЯ:
Главный редактор

Заместители главного редактора

Члены редколлегии
Специализированные редколлегии


 УЧРЕДИТЕЛИ:
Институт теоретической и экспериментальной биофизики Российской академии наук.

ООО "ИЦ КОМКОН".




Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314

Российская поисковая система
Искать: 


«
Vol. 14, Art. 61 (pp. 762-772)    |    2013       
»

Clinico-hematological parameters and effectiveness of platelets transfusions in patients with acute myeloid leukemia
Davaasambuu B. 1, Gritsaev S.V. 2, Glazanova T.V. 2, Kostroma I.I. 2, Potichonova N.A. 2, Martinkevitch I.S. 2, Koloskov A.V., Chechetkin A.V. 2
1SBIHE “Nord-Western State Medical University named after I.I. Mechnicov” under the Ministry of Public Health and Social Affairs of Russian Federation, St.Petersburg
2FSBI “Russian Research Institute of Hematology and Transfusiology of FMBA Russia”. St.Petersburg



Brief summary

The effectiveness of platelets transfusions is dependent from many different parameters of immune and nonimmune factors. The aim of the study is to evaluate the association between some of clinic-hematological parameters and platelets transfusions’ refractoriness during induction (IR) and high dose chemotherapy (HDCh) in patients with acute myeloid leukemia (AML). The data of 41 patients during IR and 58 patients during HDCh were analyzed. To determine the effectiveness of platelets effectiveness the corrected count increment of transfused platelets was used. It was revealed that the effectiveness of platelets transfusions are dependent on morphological nature of blasts and prognostic ELN variants. Refractoriness to platelets transfusions is more often event in patients with monocytic nature of bone marrow blasts during IR (r=0.337; p=0.031). Opposite situation is during HDCh as the effectiveness is dependent on ELN variant (r=0.263; p=0.045). These data demonstrated that the number of nonimmune factors may be increased by new additional factors and morphological nature of bone marrow blasts and ELN cytogenetic variants are predictors of effectiveness of platelets transfusions in patients with AML.


Key words

acute myeloid leukemia, induction chemotherapy, high-dose chemotherapy, platelets transfusions, FAB classification, WHO classification, ELN prognostic system.





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Volkova M.A., red. // Klinicheskaya onkogematologiya M: Medicina. – 2007. –P . 1120.


2. Jibyrt E. B. // Transfyziologiya. SPb.: Piter. – 2002. – P.736.


3. Platelet transfusion therapy. National Institutes of Health Consensus Conference // Transfusion Medicine Reviews – 1987. – Vol.1, N. 3. – P. 195-200.


4. Slichter S.J. Evidence-based platelet transfusion guidelines // Hematology (American Society of Hematology Education Program) – 2007. – P. 172-178.


5. Li G., Liu F., Mao X., Hu L. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation // Transfusion and apheresis science – 2011. – Vol.45, N.1. – P. 21-24.


6. Slichter S.J., Davis K., Enright H. et al. Factors affecting post transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients // Blood – 2005. – Vol.105, N.10. – P. 4106-4114.


7. Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes // Blood – 2008. – Vol.114, N.5. – P. 937-951.


8. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Cooperative Group // British journal of haematology. – 1976. – Vol.33, N.4. – P. 451-458.


9. Dohner H., Estey E.H., Amadori S. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet // Blood. – 2010. – Vol.115, N.3. – P. 453-474.


10. Cheson B.D., Bennett J.M., Kopecky K.J. et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia // Journal of clinical oncology : official journal of the American Society of Clinical Oncology. – 2003. – Vol.21, N.24. – P. 4642-4649.


11. Levin M.D., de Veld J.C., van der Holt B., van 't Veer M.B. Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study // Annals of hematology. – 2003. – Vol.82, N.6. – P. 357-362.


12. Slichter S.J. Evidence-based platelet transfusion guidelines // Hematology (Am Soc Hematol Educ Program); - 2009. – P. 159-187.


13. Doughty H.A., Murphy M.F., Metcalfe P. et al. Relative importance of immune and non-immune causes of platelet refractoriness // Vox Sanguinis. – 1994. – Vol.66, N.33. – P. 200-205.


14. Semple J.W., Italiano J.E. Jr., Freedman J. Platelets and the immune continuum // Nature reviews. Immunology. – 2011. – Vol.11, N.4. – P. 264-274.


15. Gricaev S.V., Martinkevich I.S., Martinenko L.S., Moskalenko M.V., Ivanova M.P., Aksenova V.U. i dr. Vozrast i kariotip - faktori riska y bolnih pervichnim ostrim mieloidnim leikozom // Klinicheskaya onkogematologiya. – 2010. - Vol.4. – P. 359-364.


16. Appelbaum F. ASH Educational Book // Washington. - 1999. – P. 497 – 499.


17. De vita V. In: DeVita V., Heeman S., Rosenberg S.A. Cancer. Principles and practice of oncology. -5th ed. // Philadelphia – New York, - 1997. – P. 333-347


18. Murphy M.F., Waters A.H. Platelet transfusions: The problem of refractoriness // Blood Rev – 1990. – Vol.4, N.1. – P. 16-24.


19. Paolo R. A mini-review on platelet refractoriness // Haematologica. – 2005. – Vol. 90, N.2. – P. 247-253.


20. Jackman R.P., Deng X., Bolgiano D., Lebedeva M., Heitman J.W., Busch M.P. et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants // Blood. – 2013. – Vol.121, N.16. – P. 3261-3266.


21. Murphy M.F., Metcalfe P., Ord J. et al. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions // British journal of haematology. – 1987. – Vol.67, N.3. – P. 255-260.


22. Rizzari C., Cazzaniga G., Goliva T., et al. Predictive factors and survival in childhood acute myeloid leukemia: role of minimal residual disease // Expert review of anticancer therapy. – 2011. – Vol.11, N.9. – P. 1391-401.



Свидетельство о регистрации сетевого электронного научного издания N 077 от 29.11.2006
Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций
(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции

Размещение рекламы

Rambler's Top100